I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

Similar documents
A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Abnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

Approach to the Patient with Liver Disease

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries

Disclosure. Evaluation of Abnormal Hepatic Enzymes

Interpreting Liver Function Tests

Interpreting Liver Tests What Do They Mean? Roman E. Perri, MD

EVALUATION OF ABNORMAL LIVER TESTS

HEPETIC SYSTEMS BIOCHEMICAL HEPATOCYTIC SYSTEM HEPATOBILIARY SYSTEM RETICULOENDOTHELIAL SYSTEM

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

4/27/2018. Disclosures LIVER FUNCTION TESTS LIVER FUNCTION TESTS LIVER FUNCTION TESTS APPROACH TO THE PATIENT WITH ABNORMAL LIVER TESTS

Approach to Abnormal Liver Tests

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

Extrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock.

Biochemical Investigations in Liver Disease. Dr Roshitha de Silva Department of Pathology Faculty of Medicine University of Kelaniya

What are LFTs? What are LFTs? 3/20/2017. Evaluation of Abnormal Liver Chemistry Tests. Transaminases. Alkaline phosphatase.

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

Interpreting Your Tests

Current Concepts in the Management and Treatment of PBC & PSC

9/28/2016. Elevated Liver Function Tests: A Case Based Approach. Objectives. Identify patterns of abnormal liver function tests

LIVER FUNCTION TESTS. G M Kellerman. Hunter Area Pathology Service

-Liver function tests -

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN

Not All Patients With Liver Disease Have HCV Diagnosis and Management of Some Common Non HCV Liver Diseases

A Rational Evidence-based Approach to Abnormal Liver Tests

CITY AND HACKNEY CCG ABNORMAL LIVER FUNCTION TESTS (LFTs) in ADULTS

Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark

Investigating and Referring Incidental Findings of Abnormal Liver Tests

Diagnosis and Management of PBC

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Hangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Pediatric PSC A children s tale

Overview of PSC Making the Diagnosis

ACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society

Idiopathic adulthood ductopenia manifesting as jaundice in a young male

Jaundice. Agnieszka Dobrowolska- Zachwieja, MD, PhD

Pittsburgh CME Conference November 7-9, 2014

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST

Diseases of liver. Dr. Mohamed. A. Mahdi 4/2/2019. Mob:

LIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA

Biochemistry Lecture #3

Session 11: The ABCs of LFTs Learning Objectives

Patologia sistematica V Gastroenterologia Prof. Stefano Fiorucci Autoimmune liver diseases

Liver Function Testing. in primary care. Quiz Feedback

Metabolic, Miscellaneous and Inflammatory Diseases of the Liver. 1. A 50 year old man is seen in the office for routine evaluation.

Biochemistry Liver Function Tests (LFTs)

Dhanpat Jain Yale University School of Medicine, New Haven, CT

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

Hepatology for the Nonhepatologist

GI Workshop Case Studies

Liver Network Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities

Primary Biliary Cholangitis

Dr Mere Kende. MBBS,Mmed(Path), MAACB, MACTM, MACRRM Lecturer -SMHS

Liver Network. Guidelines for the Management of Adults with Asymptomatic Liver Function Abnormalities

ELEVATED LIVER ENZYMES

Approach to the Patient with Abnormal Liver Enzymes

Acute Hepatitis: An Approach to Infectious and Other Causes. Mary Anne Cooper MSc, MD, MEd, FRCPC

Aspartate aminotransferase-to-platelet ratio index in children with cholestatic liver diseases to assess liver fibrosis

6/27/2018. Approach to Elevated Liver Tests. At the conclusion the audience should have a better understanding of

Metabolic Liver Disease

ROUTINE LAB STUDIES. Routine Clinic Lab Studies

Sarah Landes October 23, 2014

EVALUATION & LISTING. Your Child s Liver Transplant Evaluation. What is the Liver?

Monitoring Hepatitis C

Standard Liver Tests

HEPATOLOGY COPYRIGHTED MATERIAL

LFTs: an update A MacGilchrist PLIG meeting 31st January 2019

Hépatopathies auto-immunes

Drug therapy in patient with hepatic impairment

1. Based on A.S. s labs and presentation, what type of liver injury would you classify her as experiencing?

Primary Sclerosing Cholangitis Medical Management

Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014

King s College Hospital NHS Foundation Trust. Acute Liver Disease: what you really need to know.

Management of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France

LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES

CrackCast Episode 28 Jaundice

Pediatric Primary Sclerosing Cholangitis and Potential Therapies

Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto

The Primary Care Physician s Approach to Abnormal Liver Tests Brian Viviano, D.O. Medical Associates of Erie. Objectives

Learning Objectives. Case 1. Case Presentations. Interpretation of Liver Tests. Interpretation of Liver Tests. Presenter Disclosure Information

AAIM: GI Workshop Follow Up to Case Studies. Non-alcoholic Fatty Liver Disease Ulcerative Colitis Crohn s Disease

Morning Report Presentation. Sarah Hughes, MD January 11, 2005

Biliary Stones. Biliary Stones. Biliary Stones. Chapter XI K00-K93 Digestive System. ำ จ ยทางค ก (Clinical Diagnosis)

Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries

Gastroenterology. Certification Examination Blueprint. Purpose of the exam

CHAPTER 1. Alcoholic Liver Disease

Alpha-1 Liver Disease

Transcription:

LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate between hepatocellular and cholestatic liver disease Determine how to measure hepatic synthetic function Use common liver tests and exam findings to determine short and long-term survival * Recognize common adult liver disorders LIVER TESTS: WHAT IS INCLUDED? SGPT (ALT): 8-66 SGOT (AST): 13-44 Alkaline phosphatase: 40-129 Gamma-glutamyl transferase (GGT): 10-71 Total bilirubin: 0.2-1.0 Direct bilirubin (conjugated): 0-0.3 Indirect bilirubin (unconjugated) = total - direct Prothrombin time, INR: 0.9-1.3 Serum albumin: 3.8-5.0 QUESTION 1: TYPE OF LIVER DISEASE? Hepatocellular: Cholestatic/Obstructive: (ALT/AST) (alkaline phosphatase) alcohol stones viral hepatitis primary biliary cholangitis autoimmune hepatitis (PBC) hemochromatosis primary sclerosing cholangitis Wilson s Disease (PSC) Non-alcoholic fatty liver medications alpha-1 antitrypsin deficiency medications INFILTRATIVE LIVER DISEASE Space occupying lesion Alkaline phosphatase elevation Occasional bilirubin elevation Examples: tumors, amyloid, sarcoid 1

LIVER TESTS: HELPFUL HINTS Bilirubin frequently not helpful in determining type of injury Can become elevated due to hepatic as well as nonhepatic causes (hemolysis) Can become elevated in hepatocellular, cholestatic as well as infiltrative disease ALT is more specific for liver disease than the AST Alkaline phosphatase; biliary, bone, placenta, intestine GGT is nonspecific Helpful in determining the source of alkaline phosphatase elevation LIVER TESTS: HELPFUL HINTS ALT > 500 = Hepatitis A, Hepatitis B, autoimmune hepatitis, medications, ischemia (shock liver) Alcoholic liver disease rarely has transaminases >300 AST:ALT > 2:1 is suggestive of alcoholic liver disease QUESTION 2: ACUTE OR CHRONIC? INR, INR, INR Albumin CASE 1 55-year-old male with recent cardioversion for atrial fibrillation. ALT 1614 AST 1567 ALK PHOS 145 TOTAL BILI 10.3 DIRECT BILI 7.6 INR 1.2 CASE 2 63-year-old asymptomatic female. BMI 33. MEDS: amlodipine for HTN, glyburide for DM ALT 112 AST 110 ALK PHOS 102 TOTAL BILI 0.9 DIRECT BILI 0.5 INR 0.9 ALBUMIN 3.9 2

Risk factors: BMI > 30 Insulin resistance Elevated triglycerides Hispanics > Caucasians > African Americans Diagnosis of exclusion Weight loss > 10% Nonalcoholic Fatty Liver Disorder Nonalcoholic steatohepatitis Chronic Hepatitis C Alcoholic Liver Disease Hemochromatosis Chronic Hepatitis B Prevalence of Chronic Liver Disorders in the United States 1 2 3 4 5 6 0 5 10 15 20 25 Percent of Population 1. Hilden M et al. Scand J Gastroenterol. 1977;12:593-597. 2. Ground KEU. Aviat Spac Environ Med. 1982;53;14-18. 3. Alter MF et al. N Engl J Med. 1999;341:556-562. 4. Venkataramani A et al. In: Maddrey WC, Feldman M, eds. Atlas of the Liver. Philadelphia: Current Medicine;1999:9.0. 5. Adapted from http://www.nhlbi.nih.gov/new/press/01/09-25.htm. Accessed 11/01/02. 6. McQuillan GM et al. Am J Public Health 1999;89:14-18. CASE 3 46-year-old male with jaundice. EGD shows large varices. ALT 31 AST 119 ALK PHOS 98 TOTAL BILI 3.4 DIRECT BILI 1.9 INR 1.6 Transaminases < 300, AST:ALT > 2:1 Vitamin K not beneficial in hepatocellular injury and coagulopathies All patients with cirrhosis should undergo EGD to evaluate for varices If normal, repeat in three years CASE 4 A 40-year-old woman is found to have abnormal liver tests during an evaluation for pruritus of 1 year duration. Denies alcohol and takes no medications. ALT 143 AST 110 ALK PHOS 741 TOTAL BILI 3.2 DIRECT BILI 2.9 INR 2.0 Primary biliary cholangitis 90% of affected are women Anti-mitochondrial antibody (AMA) Microscopic bile ducts Pruritus = cholestasis (cholestyramine) Sicca syndrome Bone disease Hypercholesterolemia (xanthelasma) Vitamin K beneficial for coagulopathies 3

emedicine.com Tuberous Xanthomata Xanthelasma Tuberous Xanthomata CASE 5 35-year-old male with abnormal liver tests noted during routine labs for health insurance. He is asymptomatic. ALT 26 AST 21 ALK PHOS 78 TOTAL BILI 2.9 DIRECT BILI 0.2 INR 0.9 Elevated total bilirubin Conjugated (direct) versus unconjugated (indirect) Unconjugated Gilbert s versus hemolysis CASE 6 60-year-old male with fatigue and dyspnea on exertion. Father died of cirrhosis. MEDS: sildenafil, insulin, ibuprofen for knee pain ALT 86 AST 65 Alkaline Phosphatase 97 Total bilirubin 1.1 Direct bilirubin 0.4 INR 1.4 Hereditary hemochromatosis (primary) All chronic liver diseases raise iron levels (secondary) Homozygous 1/200 (Caucasian patients) Darkening of skin, DM, CHF, arthropathy Elevated ferritin (usually greater than 1000) Transferrin saturation (iron/tibc) > 45% HFE gene positive in 75-80% Treat with phlebotomy until ferritin approx. 50 CASE 7 37-year-old female with generalized malaise and fatigue. MEDS: methotrexate for rheumatoid arthritis ALT 589 AST 712 Alkaline Phosphatase 158 Total bilirubin 2.0 Direct bilirubin 1.6 INR 1.3 4

Autoimmune hepatitis > 75 % are female Anti-smooth muscle antibody positive Anti-nuclear antibody positive Elevated IgG or gamma globulins Treated with immunosuppressive therapy Corticosteroids, azathioprine CASE 8 29-year-old male with fatigue and dyspnea on exertion. ALT 76 AST 62 Alkaline Phosphatase 99 Total bilirubin 1.6 Direct bilirubin 0.9 INR 1.2 Alpha-1 antitrypsin deficiency Homozygous in 1/1600 More frequently presents in childhood Check A1AT level (pathology seen at 15-20% of normal values) Phenotype - normal MM - liver disease seen in ZZ No treatment CASE 9 38-year-old male with jaundice and malaise. ALT 29 AST 96 ALK PHOS 98 TOTAL BILI 12 DIRECT BILI 8 PT 19 SEC CONTROL PT 12 SEC Alcoholic hepatitis Transaminases < 300, AST:ALT > 2:1 Discriminant function 4.6(PT-PT control) + total bilirubin Values > 32 at high risk for 30-day mortality May benefit from steroids if no infectious contraindications 4.6(19-12)+12 Discriminant Fct: 44 5

CASE 10 40-year-old male with jaundice, pruritus and diarrhea. AST 52 ALT 58 ALK PHOS 516 TOTAL BILI 6.3 DIRECT BILI 4.1 INR 1.8 Primary sclerosing cholangitis (PSC) Two-thirds with inflammatory bowel disease Large duct disease No associated autoantibody Imaging with MRCP/ERCP PRIMARY SCLEROSING CHOLANGITIS ON MRCP PRIMARY SCLEROSING CHOLANGITIS Radiology Assistant CHILD-TURCOTTE-PUGH CLASSIFICATION 5-YEAR SURVIVAL A = 70-75% B = 40-45% C = 10-15% 6

MODEL FOR END-STAGE LIVER DISEASE (MELD) MELD AND 3 MONTH SURVIVAL Wiesner et al. Gastroenterology 2003 BONUS Food impactions without evidence of mechanical obstruction: PREDICTING MORTALITY IN PATIENTS WITH CIRRHOSIS UNDERGOING SURGERY MELD SCORE AS A PREDICTOR OF POST OPERATIVE MORTALITY MELD score 7 Days 30 Days 90 Days 0 7 (n = 351) 1.9 (314) 5.7 (301) 9.7 (287) 8 11 (n = 257) 3.3 (236) 10.3 (219) 17.7 (200) 12 15 (n = 106) 7.7 (94) 25.4 (78) 32.3 (69) 16 20 (n = 35) 14.6 (29) 44.0 (19) 55.8 (15) 21 25 (n = 13) 23.0 (7) 53.8 (4) 66.7 (3) >26 (n = 10) 30.0 (6) 90.0 (1) 90.0 (1) Modified from Ray Kim et al; GASTROENTEROLOGY 2007;132:1261 1269 THANK YOU!!! 7